Takeda Turnaround In Full Flow As New Products Deliver On Promise
Takeda Pharmaceutical Co. Ltd. has closed out its "turnaround year" on target, meeting guidance for fiscal 2015. The company has been undergoing a reorganization to pull it through intense generic competition and CEO Christophe Weber took the year-end opportunity to outline how the strategy was playing out for Japanese pharma.
You may also be interested in...
AstraZeneca is to pay $575m to acquire full rights to Takeda's Daxas (roflumilast), along with other respiratory assets. The move is the latest in a series of bolt-on acquisitions by the UK firm to bulk up its position in respiratory, one of its core therapeutic franchises along with oncology and cardiovascular/metabolic.
Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Co. Ltd. are to create a joint business venture to boost the supply of generics to the Japanese market. The new business will be 51% owned by Teva and 49% by Takeda.